新闻资讯
/
/
Qijian News

Great News! Qijian has obtained the human growth hormone (HGH) API export license signed and approved by the Food and Drug Administration。

In early 2022, Jilin Provincial Food and Drug Administration announced our "Drug export license for anabolic agents and peptide hormones" on website, it means that Qijian has become an approved enterprise for export human growth hormone (HGH) API in Jilin Province. Moreover in April 2021 Qijian obtained the "Drug Production License" for product HGH which updated and issued by CFDA, and the quality of HGH products meet the US FDA and EU GMP standards. In the new year, we will continue to improve our management level and provide customers with better products. 注: 出口准许证获批公示连接地址 吉林省药品监督管理局核(换)发《药品生产许可证》公告(2022年第1期)公示连接地址 药品生产许可查询地址  
24 2022/01

ijian Bio-pharmaceutical made a major breakthrough in the R&D of key transdermal technology using HGH analogue peptides as raw materials for medical beauty products, laying a good foundation for the company to expand the medical beauty industry in 2021.

ijian Bio-pharmaceutical made a major breakthrough in the R&D of key transdermal technology using HGH analogue peptides as raw materials for medical beauty products, laying a good foundation for the company to expand the medical beauty industry in 2021.
01 2021/12

Qijian was invited to participate in "China Service Trade Fair 2021”

Our company was invited to participate in the "China Service Trade Fair 2021" which held in Beijing from September 4 to 7, 2021, Li Wei, Vice Governor of Jilin Province, visited Qijian 's booth, he encouraged us to strengthen exchanges and promote the development of service trade.
10 2021/09

Butylphthalide Injection

We applied for registration of product Butylphthalide Injection and on July 15,2021 received the notification from CFDA(Acceptance number: CXHL2101298国), "Butylphthalide Injection" Class II New Drugs enters the Clinical Phase.
30 2021/07

Annual examination of drug production license passed

Our company's ''drug production license'' annual review has recently been passed, including human recombinant growth hormone (raw drug, freeze-dried powder injection) and so on.
30 2021/07

成功签署合作开发抗病毒药物项目

2021年9月20日,公司董事长席玥女士及首席医学官牛俊奇先生与受邀到访公司的北京陆军总医院(原北京301医院)的抗病毒疫苗的研发团队进行了深入交流,并对今后进一步开发抗病毒药物项目签署了合作意向。
21 2021/09
Previous page
1
2
3
4
5
6

Contact Us

Contact us

Username used for comment:
客户留言
Description:
WeChat

WeChat

Contact Us

Contact Us

ADD: No.707 Chaofan street, High-Tech Industrial Development Zone, Changchun City, Jilin province, China
Service Hotline:0086-
431-81285900
Fax:0086-431-88794098
Email:
export@qijianbio.com

Copyright:Jilin Qijian Bio-pharmaceutical Co., Ltd.  by:300.cn  吉ICP备20003293号  SEO

搜索
Search